The Enterprise Value as of December 2024 (TTM) for Lyell Immunopharma, Inc. (LYEL) is 131.58M

According to Lyell Immunopharma, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 131.58M. This represents a change of -65.69% compared to the average of 383.53M of the last 4 quarters.

Lyell Immunopharma, Inc. (LYEL) Historical Enterprise Value (quarterly & annually)

How has LYEL Enterprise Value performed in the past?

The mean historical Enterprise Value of Lyell Immunopharma, Inc. over the last ten years is 2.21B. The current 131.58M Enterprise Value has changed 496.30% with respect to the historical average. Over the past ten years (40 quarters), LYEL's Enterprise Value was at its highest in in the March 2020 quarter at 4.01B. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Lyell Immunopharma, Inc. (LYEL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Lyell Immunopharma, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Lyell Immunopharma, Inc. (LYEL) Average Enterprise Value

How has LYEL Enterprise Value performed in the past?

The current Enterprise Value of Lyell Immunopharma, Inc. (LYEL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Lyell Immunopharma, Inc. (LYEL) Enterprise Value vs. Peers

How is LYEL’s Enterprise Value compared to its peers?

Lyell Immunopharma, Inc.’s Enterprise Value is less than Cullinan Oncology, Inc. (603.75M), less than Monte Rosa Therapeutics, Inc. (355.55M), less than Theseus Pharmaceuticals, Inc. (138.26M), less than Revolution Medicines, Inc. (7.92B), less than Nkarta, Inc. (195.74M), less than Generation Bio Co. (144.59M), less than Sana Biotechnology, Inc. (358.69M), less than Nuvation Bio Inc. (888.20M), greater than Century Therapeutics, Inc. (86.28M), greater than Shattuck Labs, Inc. (12.77M), less than Crinetics Pharmaceuticals, Inc. (4.74B), greater than Inhibrx Biosciences, Inc. (12.51M), less than Merus N.V. (2.50B), greater than Kronos Bio, Inc. (8.02M), less than Edgewise Therapeutics, Inc. (2.79B), less than C4 Therapeutics, Inc. (274.98M), less than Mineralys Therapeutics, Inc. (533.05M),

Build a custom stock screener for Lyell Immunopharma, Inc. (LYEL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lyell Immunopharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lyell Immunopharma, Inc. (LYEL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lyell Immunopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.